StockNews.com upgraded shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) from a sell rating to a hold rating in a ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Ligand Pharma (LGND – Research Report), with a price target ...

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL ...

Ligand Pharmaceuticals Inc (NASDAQ:LGND) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 revenue is $39.02 million, and the earnings are expected to come ...

Ligand Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $1.27 EPS, expectations were $1.37. Melanie Herman: Good morning everyone and welcome to Ligand’s Fourth ...

Despite a GAAP net loss, Ligand Pharmaceuticals Inc (LGND) showcases robust financial health and promising new ventures in its latest earnings call. JUPITER, Fla. AP) — Ligand Pharmaceuticals ...

Revenue guidance for 2025 is set between $180 million and $200 million. Ligand Pharmaceuticals demonstrated robust growth in 2024, with total revenue increasing by 27% to $167.1 million from $131. ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Ligand Pharma (LGND – Research Report), with a price target of $160.00. The company’s shares closed yesterday ...

Limited or Ligand Pharmaceuticals Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

JUPITER, Fla. (AP) — JUPITER, Fla. (AP) — Ligand Pharmaceuticals Inc. (LGND) on Thursday reported a loss of $31.1 million in its fourth quarter. On a per-share basis, the Jupiter, Florida ...

(RTTNews) - Biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND), while reporting a loss in its fourth quarter, compared to prior year's profit, on Thursday confirmed fiscal 2025 forecast.